← Back

Wire · opportunities

J&J's Caplyta hits primary endpoint in bipolar mania, supporting FDA filing

Published

11 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at allsci.com →

◆ Verified

Fusion42 · 11 November 2026 · Fusion42 review

Johnson & Johnson's Caplyta (lumateperone) demonstrated positive efficacy in a second pivotal Phase III trial for bipolar I manic episodes, showing significant symptom reduction versus placebo and supporting an upcoming FDA filing for this new indication.

This Wire brief sits within Fusion42's coverage of Biotech, and 1 source has reported it between 11 Nov 2026 and 20 Nov 2026.

◆ ◆ The Wire takeaway

You need to watch how approval of Caplyta for bipolar mania shifts treatment options in mental health. This FDA move opens a door to provide a broader therapy and challenges current mania drugs.

◆ Coverage

1 source · first reported 11 Nov 2026 · latest 20 Nov 2026

◆ Related on Wire

◆ Topics

Biotechbipolar-maniaclinical-trialdrug-approvalJ&JFDA-filing